Showing 7041-7050 of 7739 results for "".
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- Study: Primary Care Melanoma Screening Does Not Lead to Overtreatmenthttps://practicaldermatology.com/news/study-primary-care-melanoma-screening-does-not-lead-to-overtreatment/2458506/Melanoma screening in primary care practice does not lead to overtreatment, new research suggests. In the new study, primary care providers at the University of Pittsburgh Medical Center system received online training in melanoma screening and began looking for the skin cancers in
- FDA Greenlights First-Ever OTC Retinoidhttps://practicaldermatology.com/news/fda-greenlights-first-ever-otc-retinoid/2458507/The U.S. Food and Drug Administration (FDA) approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne in people 12 years of age and older. Differin Gel 0.1% is the first retinoid to be made available OTC for the
- Allergan Vet Julian S. Gangolli Joins Revance's Board of Directorshttps://practicaldermatology.com/news/allergan-vet-julian-s-gangolli-joins-revances-board-of-directors/2458508/Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016. He will help Revance progress toward regulatory approv
- Sciton Launches New Program to Encourage Practice Growthhttps://practicaldermatology.com/news/sciton-launches-new-program-to-encourage-practice-growth/2458510/Sciton Inc. is unveiling their new practice support program. With Success Builder, Sciton offers four specialized pillars: clinical training, marketing tools, business development, and Sciton-sanctioned tools and courses. Many of the vendors also o
- It's Official: Botox Makes Us Feel Better About Ourselveshttps://practicaldermatology.com/news/its-official-botox-makes-us-feel-better-about-ourselves/2458516/Patient satisfaction with overall facial appearance increases by 28 percent with botulinum toxin type A injections to the glabellar rhytids, according to new research in the Aesthetic Surgery Journal. In the study, sati
- Allergan Research: Women Seek Confidence Over Youthhttps://practicaldermatology.com/news/allergan-research-women-seek-confidence-over-youth/2458517/The desire to boost self-confidence is as important as tightening sagging skin among women seeking aesthetic treatments, according to new research from Allergan. The Changing Face of Beauty: A Global Report' comprises opinions on beauty and
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e